Drug intelligence / Profile preview

VRT106 + camrelizumab + apatinib

Development stage: Unknown
Lead developer: Guangzhou Virotech Pharmaceutical
Modality: Small Molecules, Oncolytic Viruses → Oncolytic Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous, Oral

Overview

VRT106 + camrelizumab + apatinib is a combination therapy being investigated for the treatment of advanced hepatocellular carcinoma (HCC), particularly in patients who have failed prior immune checkpoint inhibitor (ICI) therapy. VRT106 (also known as M1-c6v1) is an oncolytic alphavirus (M1 virus) developed by Guangzhou Virotech Pharmaceutical that selectively replicates in and kills zinc-finger antiviral protein (ZAP)-deficient cancer cells. Camrelizumab is a humanized monoclonal antibody targeting the programmed cell death protein 1 (PD-1) receptor, while apatinib is a small-molecule tyrosine kinase inhibitor that selectively inhibits vascular endothelial growth factor receptor 2 (VEGFR-2). The combination aims to leverage the direct oncolytic effect and immune-priming of VRT106 alongside the checkpoint blockade of camrelizumab and the anti-angiogenic properties of apatinib to overcome resistance in HCC.

Other names: M1-c6v1 + camrelizumab + apatinib

Targets

VEGFR2 (Vascular endothelial growth factor receptor 2)KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on VRT106 + camrelizumab + apatinib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VRT106 + camrelizumab + apatinib.

Explore the full profile